Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress

DUBLIN--(BUSINESS WIRE)--Horizon Pharma will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for thyroid eye disease.

Full Story →